Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: Differences between Non-Hodgkin's Lymphoma and Hodgkin's disease

Quarterly Journal of Nuclear Medicine

Volumn 45, Issue 3, 2001, Pages 269-273

  Spaepen, K ^a   Mortelmans, Luc ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Fluorodeoxyglucose F18; Hodgkin disease, radionuclide imaging; Lymphoma, non Hodgkin, radionuclide imaging; Tomography, emission computed

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GALLIUM 67;

ALGORITHM; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DRUG MONITORING; DRUG RESPONSE; DRUG UPTAKE; EARLY DIAGNOSIS; EVALUATION; FOLLOW UP; HODGKIN DISEASE; HUMAN; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOLOGICAL ANATOMY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PUBLICATION; REVIEW; SALVAGE THERAPY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

FLUORINE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0035722677     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients?
2. Prognostic factors in aggressive malignant lymphomas. Description and validation of prognostic index that could identify patients requiring a more intensive therapy
3. Residual mass in lymphoma may not be residual disease
4. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma
5. Gallium scan in the evaluation of post chemotherapy mediastinal residual masses of aggressive non-Hodgkin's lymphoma
6. Early chemotherapy response monitoring with FDG in a tumor-mouse model: Does FDG uptake correlate with viable cell fraction?
7. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma
8. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
9. Extranodal malignant lymphoma: Detection with FDG-PET versus CT
10. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose
11. 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease
12. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: Is it time to shift gears?
13. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
14. 18F FDG-PET a valid alternative to conventional diagnostic methods?
15. Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography
16. Staging of Burkitt's lymphoma and response to treatment monitored by PET scanning
17. Thyroid, pulmonary and cardiac sequelae after treatment for Hodgkin's disease
18. Incidence of second cancers in patients treated for Hodgkin's disease
19. The residual mediastinal mass following radiation therapy for Hodgkin's disease
20. 18F FDG-PET) after first line treatment distinguish Hodgkin's disease patients who need additional therapy from others where additional therapy would mean avoidable toxicity?
21. Problems in Hodgkin's disease management